Journal of International Oncology››2021,Vol. 48››Issue (7): 433-435.doi:10.3760/cma.j.cn371439-20201230-00083
• Reviews •Previous ArticlesNext Articles
Yang Yinjing, Li Guixiang(), Tang Min
Received:
2020-12-30Revised:
2021-04-01Online:
2021-07-08Published:
2021-07-26Contact:
Li Guixiang E-mail:lgx.doctor.007@163.comYang Yinjing, Li Guixiang, Tang Min. Research progress of fibrinogen, NLR and F-NLR grading in gastric cancer[J]. Journal of International Oncology, 2021, 48(7): 433-435.
[1] | Thrift AP, El-Serag HB. Burden of gastric cancer[J]. Clin Gastroenterol Hepatol, 2020, 18(3):534-542. DOI: 10.1016/j.cgh.2019.07.045. doi:10.1016/j.cgh.2019.07.045 |
[2] | Arnold M, Abnet CC, Neale RE, et al. Global burden of 5 major types of gastrointestinal cancer[J]. Gastroenterology, 2020, 159(1):335-349, e15. DOI: 10.1053/j.gastro.2020.02.068. doi:10.1053/j.gastro.2020.02.068 |
[3] | Chen L, Yan Y, Zhu L, et al. Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy[J]. Cancer Manag Res, 2017, 9:849-867. DOI: 10.2147/CMAR.S151026. doi:10.2147/CMAR.S151026pmid:29276407 |
[4] | Kurokawa Y, Doki Y, Mizusawa J, et al. Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2018, 3(7):460-468. DOI: 10.1016/S2468-1253(18)30090-6. |
[5] | Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration[J]. Ann Intern Med, 2015, 162(1):W1-W73. DOI: 10.7326/M14-0698. doi:10.7326/M14-0698 |
[6] | Matsuoka T, Yashiro M. Biomarkers of gastric cancer: current topics and future perspective[J]. World J Gastroenterol, 2018, 24(26):2818-2832. DOI: 10.3748/wjg.v24.i26.2818. doi:10.3748/wjg.v24.i26.2818 |
[7] | Karki R, Man SM, Kanneganti TD. Inflammasomes and cancer[J]. Cancer Immunol Res, 2017, 5(2):94-99. DOI: 10.1158/2326-6066.CIR-16-0269. doi:10.1158/2326-6066.CIR-16-0269 |
[8] | Yu X, Hu F, Yao Q, et al. Serum fibrinogen levels are positively correlated with advanced tumor stage and poor survival in patients with gastric cancer undergoing gastrectomy: a large cohort retrospective study[J]. BMC Cancer, 2016, 16:480. DOI: 10.1186/s12885-016-2510-z. doi:10.1186/s12885-016-2510-z |
[9] | Miyamoto R, Inagawa S, Sano N, et al. The neutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients[J]. Eur J Surg Oncol, 2018, 44(5):607-612. DOI: 10.1016/j.ejso.2018.02.003. doi:S0748-7983(18)30296-8pmid:29478743 |
[10] | Cong X, Li S, Zhang Y, et al. The combination of preoperative fibrinogen and neutrophil-lymphocyte ratio is a predictive prognostic factor in esophagogastric junction and upper gastric cancer[J]. J Cancer, 2019, 10(22):5518-5526. DOI: 10.7150/jca.31162. doi:10.7150/jca.31162 |
[11] | Repetto O, De Re V. Coagulation and fibrinolysis in gastric cancer[J]. Ann N Y Acad Sci, 2017, 1404(1):27-48. DOI: 10.1111/nyas.13454. doi:10.1111/nyas.13454 |
[12] | Lin Y, Liu Z, Qiu Y, et al. Clinical significance of plasma D-dimer and fibrinogen in digestive cancer: a systematic review and meta-analysis[J]. Eur J Surg Oncol, 2018, 44(10):1494-1503. DOI: 10.1016/j.ejso.2018.07.052. doi:10.1016/j.ejso.2018.07.052 |
[13] | Wang H, Zhao J, Zhang M, et al. The combination of plasma fibri-nogen and neutrophil lymphocyte ratio (F-NLR) is a predictive factor in patients with resectable non small cell lung cancer[J]. J Cell Physiol, 2018, 233(5):4216-4224. DOI: 10.1002/jcp.26239. doi:10.1002/jcp.v233.5 |
[14] | Sun Y, Zhang Y, Huang Z, et al. Combination of preoperative plasma fibrinogen and neutrophil-to-lymphocyte ratio (the F-NLR score) as a prognostic marker of locally advanced rectal cancer following preoperative chemoradiotherapy[J]. World J Surg, 2020, 44(6):1975-1984. DOI: 10.1007/s00268-020-05407-3. doi:10.1007/s00268-020-05407-3 |
[15] | Yamamoto M, Kurokawa Y, Kobayashi N, et al. Prognostic value of the combined index of plasma fibrinogen and the neutrophil-lymphocyte ratio in gastric cancer[J]. World J Surg, 2020, 44(1):207-212. DOI: 10.1007/s00268-019-05193-7. doi:10.1007/s00268-019-05193-7pmid:31559484 |
[16] | Grafetstätter M, Hüsing A, González Maldonado S, et al. Plasma fibrinogen and sP-selectin are associated with the risk of lung cancer in a prospective study[J]. Cancer Epidemiol Biomarkers Prev, 2019, 28(7):1221-1227. DOI: 10.1158/1055-9965.EPI-18-1285. doi:10.1158/1055-9965.EPI-18-1285 |
[17] | Yamamoto M, Kurokawa Y, Miyazaki Y, et al. Usefulness of preo-perative plasma fibrinogen versus other prognostic markers for predicting gastric cancer recurrence[J]. World J Surg, 2016, 40(8):1904-1909. DOI: 10.1007/s00268-016-3474-5. doi:10.1007/s00268-016-3474-5pmid:26969673 |
[18] | Huang C, Liu Z, Xiao L, et al. Clinical significance of serum CA125, CA19-9, CA72-4, and fibrinogen-to-lymphocyte ratio in gastric cancer with peritoneal dissemination[J]. Front Oncol, 2019, 9:1159. DOI: 10.3389/fonc.2019.01159. doi:10.3389/fonc.2019.01159pmid:31750248 |
[19] | Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents[J]. Nat Rev Clin Oncol, 2015, 12(10):584-596. DOI: 10.1038/nrclinonc.2015.105. doi:10.1038/nrclinonc.2015.105 |
[20] | Chmiela M, Karwowska Z, Gonciarz W, et al. Host pathogen inte-ractions in Helicobacter pylori related gastric cancer[J]. World J Gastroenterol, 2017, 23(9):1521-1540. DOI: 10.3748/wjg.v23.i9.1521. doi:10.3748/wjg.v23.i9.1521 |
[21] | Piciucchi M, Stigliano S, Archibugi L, et al. The neutrophil/lymphocyte ratio at diagnosis is significantly associated with survival in metastatic pancreatic cancer patients[J]. Int J Mol Sci, 2017, 18(4):730. DOI: 10.3390/ijms18040730. doi:10.3390/ijms18040730 |
[22] | Yodying H, Matsuda A, Miyashita M, et al. Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: a systematic review and meta-analysis[J]. Ann Surg Oncol, 2016, 23(2):646-654. DOI: 10.1245/s10434-015-4869-5. doi:10.1245/s10434-015-4869-5 |
[23] | Li S, Lan X, Gao H, et al. Systemic inflammation response index (SIRI), cancer stem cells and survival of localised gastric adenocarcinoma after curative resection[J]. J Cancer Res Clin Oncol, 2017, 143(12):2455-2468. DOI: 10.1007/s00432-017-2506-3. doi:10.1007/s00432-017-2506-3 |
[24] | Kwon BS, Jeong DH, Byun JM, et al. Prognostic value of preoperative lymphocyte-monocyte ratio in patients with ovarian clear cell carcinoma[J]. J Cancer, 2018, 9(7):1127-1134. DOI: 10.7150/jca.24057. doi:10.7150/jca.24057 |
[25] | Cupp MA, Cariolou M, Tzoulaki I, et al. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies[J]. BMC Med, 2020, 18(1):360. DOI: 10.1186/s12916-020-01817-1. doi:10.1186/s12916-020-01817-1 |
[26] | Foley JH, Conway EM. Cross talk pathways between coagulation and inflammation[J]. Circ Res, 2016, 118(9):1392-1408. DOI: 10.1161/CIRCRESAHA.116.306853. doi:10.1161/CIRCRESAHA.116.306853 |
[27] | Liu X, Liu Z, Lin E, et al. A cumulative score based on preoperative fibrinogen and the neutrophil-lymphocyte ratio to predict outcomes in resectable gastric cancer[J]. Cancer Manag Res, 2018, 10:3007-3014. DOI: 10.2147/CMAR.S174656. doi:10.2147/CMAR |
[28] | Tianxing G, Xiaojie P, Lihuan Z, et al. Combination of preoperative fibrinogen and neutrophil to lymphocyte ratio is a predictive prognostic factor in ESCC and AEG systematic review[J]. Biosci Rep, 2019, 39(10): BSR20190480. DOI: 10.1042/BSR20190480. |
[29] | Yang J, Ma J, Cheng S, et al. The combination of plasma fibrinogen concentration and neutrophil lymphocyte ratio (F-NLR) as a prognostic factor of epithelial ovarian cancer[J]. Onco Targets Ther, 2020, 13:7283-7293. DOI: 10.2147/OTT.S264118. doi:10.2147/OTT.S264118 |
[1] | Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma: a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[4] | Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266. |
[5] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[6] | Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197. |
[7] | Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209. |
[8] | Yao Yixin, Shen Yulin.Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222. |
[9] | Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150. |
[10] | Xie Shuping, Sun Yahong, Wang Chao.Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 157-165. |
[11] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[12] | Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185. |
[13] | Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82. |
[14] | Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104. |
[15] | Huang Zhen, Chen Yongshun.Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2024, 51(1): 59-64. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||